{"id":"short-term-sintilimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL4297829","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sintilimab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells and immune cells. This blockade restores anti-tumor immune responses by reactivating exhausted T cells. The drug is used in short-term treatment regimens for various malignancies.","oneSentence":"Sintilimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:07:53.898Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"},{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"},{"name":"Esophageal squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07127497","phase":"PHASE2","title":"Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Anhui Medical University","startDate":"2022-06-01","conditions":"Pathological Complete Response, Rectal Cancer, Neoadjuvant Chemoimmunotherapy","enrollment":50},{"nctId":"NCT06487429","phase":"PHASE2","title":"Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-05-08","conditions":"Gastric Cancer","enrollment":28},{"nctId":"NCT05843292","phase":"PHASE4","title":"Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-07-01","conditions":"Triple-negative Breast Cancer","enrollment":48},{"nctId":"NCT03820596","phase":"PHASE1, PHASE2","title":"Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL","status":"COMPLETED","sponsor":"Huiqiang Huang","startDate":"2019-03-29","conditions":"Safety and Efficacy","enrollment":40},{"nctId":"NCT04994210","phase":"PHASE2","title":"Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-10-04","conditions":"Safety and Efficacy","enrollment":30},{"nctId":"NCT05008666","phase":"PHASE2","title":"Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Safety and Efficacy","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Short-term Sintilimab","genericName":"Short-term Sintilimab","companyName":"Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sintilimab is an antibody that acts as a programmed cell death protein 1 antagonist. It is being studied in combination with taxane and carboplatin for neoadjuvant therapy in triple-negative breast cancer, as well as in rectal cancer, among other conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}